Personalis (NASDAQ:PSNL) Shares Gap Down Following Insider Selling

Personalis, Inc. (NASDAQ:PSNL)’s stock price gapped down prior to trading on Wednesday after an insider sold shares in the company. The stock had previously closed at $8.73, but opened at $7.95. Personalis shares last traded at $7.5480, with a volume of 616,937 shares trading hands.

Specifically, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the transaction, the chief executive officer directly owned 148,486 shares in the company, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PSNL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. Needham & Company LLC lifted their price objective on Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Lake Street Capital restated a “buy” rating and issued a $11.00 price objective on shares of Personalis in a report on Wednesday. Finally, HC Wainwright lifted their target price on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Personalis has an average rating of “Moderate Buy” and a consensus target price of $9.33.

Personalis Price Performance

The business has a 50 day moving average price of $7.33 and a 200 day moving average price of $6.05. The firm has a market capitalization of $615.38 million, a P/E ratio of -7.88 and a beta of 1.92.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $14.50 million for the quarter, compared to the consensus estimate of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts expect that Personalis, Inc. will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Large investors have recently bought and sold shares of the stock. Aberdeen Group plc increased its position in shares of Personalis by 472.3% during the 1st quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock worth $5,984,000 after purchasing an additional 1,406,895 shares in the last quarter. Geode Capital Management LLC raised its position in Personalis by 165.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after purchasing an additional 851,422 shares during the last quarter. Blue Water Life Science Advisors LP boosted its stake in Personalis by 42.6% in the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after purchasing an additional 500,900 shares in the last quarter. ARK Investment Management LLC raised its holdings in shares of Personalis by 6.1% in the first quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company’s stock valued at $25,231,000 after buying an additional 412,762 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Personalis by 1,172.0% during the second quarter. Ameriprise Financial Inc. now owns 329,865 shares of the company’s stock worth $2,164,000 after purchasing an additional 303,933 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.